DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS

DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS Stock

DE000MG0D821

Real-time Bid/Ask 01:27:24 2024-06-11 pm EDT
1.35 ^EUR / 1.47 ^EUR	+46.87%

Current month	+24.68%
1 month	+71.43%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart MADRIGAL PHARMACEUTICALS, INC.

Chart DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS

Latest news about MADRIGAL PHARMACEUTICALS, INC.

Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM	08:40am
Madrigal Pharmaceuticals Reports Positive Results in New Analysis of Phase 3 Trial of NASH Drug Rezdiffra	Jun. 06	MT
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress	Jun. 06	AQ
Madrigal Pharmaceuticals, Inc. Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra Presented at the EASL Congress	Jun. 06	CI

More news

Quotes 5-day view

Date	Price	Change
24-06-11	1.22	+27.08%
24-06-10	0.96	+12.94%
24-06-07	0.85	+1.19%
24-06-06	0.84	+6.33%
24-06-05	0.79	-19.39%

Delayed Quote Börse Stuttgart

Last update June 11, 2024 at 11:24 am EDT

More quotes

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	MADRIGAL PHARMACEUTICALS, INC.
Issuer	Morgan Stanley
WKN	MG0D82
ISIN	DE000MG0D821
Date issued	2024-03-18
Strike	350 $
Maturity	2024-12-20 (192 Days)
Parity	10 : 1
Emission price	1.46 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.68 €
Lowest since issue	0.53 €
Spread	0.12 €
Spread %	8.11%

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-Î² (THR-Î²) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Sector

More about the company

Consensus: Madrigal Pharmaceuticals, Inc.

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

254.9 USD

Average target price

365.1 USD

Spread / Average Target

+43.23%

Consensus